PAYS stock forecast, quote, news & analysis
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions... Show more
Why PaySign (PAYS) Stock Is Up +62% in the Last 30 Days
Key Takeaways
- PaySign (PAYS) shares climbed roughly 62% over the 30-day period, rising from an adjusted close of $8.69 to about $14.09.
- The move was driven primarily by better-than-expected second-quarter 2026 results reported on August 5, 2026, including a 48% year-over-year revenue increase and a raised full-year outlook.
- Patient Affordability revenue surged nearly 89% year-over-year, while the plasma segment showed a continued recovery.
- Analysts responded with higher price targets and a consensus "Buy" rating, and the stock reached a new 52-week high.
- The quarterly trend is even stronger, with shares roughly doubling over the trailing three months.
PaySign (PAYS) Company Overview and Market Position
PaySign, Inc. (NASDAQ: PAYS) is a Henderson, Nevada-based financial technology company that provides prepaid card programs, patient affordability offerings, digital banking, and integrated payment processing services. Founded in 2001, the company serves pharmaceutical manufacturers, plasma collection centers, corporations, and government institutions through its cloud-based Paysign platform.
The business is built around two core verticals. Its Patient Affordability solutions help pharmaceutical companies administer copay assistance and reimbursement programs, while its plasma segment provides prepaid donor compensation cards to plasma collection centers. PaySign has also expanded into life science technology through its Apherion donor management system, which is currently under regulatory review. Investors follow the stock for its exposure to high-growth healthcare payment niches, its recurring revenue model, and its track record of expanding margins and profitability.
PaySign (PAYS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PaySign shares advanced approximately 62%, moving from an adjusted closing price of $8.69 to about $14.09. The rally accelerated sharply after the company reported second-quarter results, with the stock jumping 29% in a single session as trading volume expanded well above its daily average.
The quarterly picture is even more pronounced. Roughly three months earlier, shares traded near $6.72, meaning the stock has roughly doubled—up about 110%—over the trailing quarter. This sustained upward trend reflects a combination of improving fundamentals, a plasma inventory overhang that has largely normalized, and accelerating growth in the higher-margin Patient Affordability business.
What Drove PAYS Stock Price in the Last 30 Days
The primary catalyst for the 30-day surge was PaySign's second-quarter 2026 earnings report, released after the market close on August 5, 2026. The company posted total revenue of $28.25 million, up 48.1% year-over-year and above consensus estimates, while earnings per share of $0.11 beat the consensus forecast of $0.06 by $0.05.
Growth was led by the Patient Affordability segment, where revenue increased 88.9% year-over-year to $14.6 million on higher claim volume and the launch of 13 new programs, bringing the total to 148 active programs. Plasma revenue rose 21.4% to $13.0 million, and average monthly revenue per center reached its highest level since the third quarter of 2024. Gross margin expanded 170 basis points to 63.3%, while adjusted EBITDA grew 113% to $9.6 million.
Management also raised its full-year 2026 guidance to revenue of $114 million to $117 million (implying 39% to 43% growth) and adjusted EBITDA of $35 million to $38 million, alongside above-consensus third-quarter guidance. Analysts reacted quickly, with DA Davidson, Lake Street Capital, and Barrington Research raising price targets following the report. The stock subsequently set a new 52-week high as institutional and retail interest increased.
What Drove PAYS Stock Performance Over the Last Quarter
The quarterly rally reflects a broader re-rating of PaySign as its business model demonstrated operating leverage at scale. Over the trailing three months, the company has consistently shown that Patient Affordability revenue can sustain rapid growth while the plasma segment recovers from the inventory overhang that pressured results through 2025.
Investor sentiment also improved as PaySign signaled international ambitions, establishing an Ireland-based subsidiary to pursue a global plasma software market opportunity. The company's dynamic business rules technology has shielded clients from more than $300 million in costs in the first half of 2026, reinforcing the value proposition behind its platform. Together, these developments shifted the narrative from a recovering plasma provider to a diversified healthcare payments growth story, supporting the stock's sustained upward trend.
Trending AI Robots
For traders seeking a data-driven approach to stocks like PaySign, Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only top-performing and most relevant bots appear in this section. These bots vary in strategy, timeframe, and performance metrics, giving users a range of approaches to explore. The page serves as a useful starting point for those interested in how AI-driven trading tools identify and respond to market patterns. Those looking to complement their own analysis may find the section worth reviewing.
PAYS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will monitor PaySign's third-quarter 2026 results, with the company guiding for revenue of $28.5 million to $30.0 million and EPS of $0.09 to $0.10. Seasonal patterns typically moderate pharmaceutical claim volume in the second half of the year, so sequential growth trends will be closely watched.
Key items on the horizon include the timing of FDA review for the Apherion donor management system, progress on international expansion through the new Ireland subsidiary, and the pace of new patient affordability program wins. Investors should also weigh concentration risk in the Patient Affordability segment, continued plasma center consolidation, and an expected rise in the effective tax rate later in the year. These factors may influence how the market assesses PaySign's growth trajectory and valuation in the coming quarters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PAYS in -3.84% downward trend, declining for three consecutive days on September 01, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PAYS declined for three days, in 226 of 268 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PAYS moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 22 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Momentum Indicator moved below the 0 level on September 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PAYS as a result. In 66 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for PAYS turned negative on August 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
PAYS broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 59 cases where PAYS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +3.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAYS advanced for three days, in 242 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 188 of 230 cases where PAYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PAYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.210) is normal, around the industry mean (22.181). P/E Ratio (50.038) is within average values for comparable stocks, (120.106). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.993). PAYS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). P/S Ratio (8.039) is also within normal values, averaging (109.949).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of payment solutions
Industry ComputerCommunications